Bioavailability of four different pharmaceutical preparations of carbamazepine.
The bioavailabilities of two tablet brands carbamazepine (CBZ) (Tegretol, A; Neurotol, B) were compared with two new experimental preparations (C,D). Formulation A showed a more sustained release nature than did the other formulations. The AUCs0 leads to infinity gave no significant differences between treatment A and three other treatments. However, if AUC0 leads to 72 was calculated instead of AUC0 leads to infinity, the preparation A gave the significantly lower bioavailability than the other compounds. Formulations A and B are marketed as generically equivalent preparations in Finland. However, their pharmacokinetic parameters after a single dose were different.
D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D002220:Carbamazepine / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D002986:Clinical Trials as Topic; D006801:Humans; D013678:Technology, Pharmaceutical
D002220:Carbamazepine